U.S. Regulator Adds to Confusion Around Heated Tobacco Products

The terminology used in the U.S. Food and Drug Administration’s (FDA) ruling on IQOS as a Modified Risk Tobacco Product creates room for misinterpretation and inaccurate representation. Even though IQOS, Philip Morris International’s (PMI) flagship heated tobacco product (HTP), did not meet the FDA’s risk modification criteria, PMI is misconstruing the agency’s decision as a “milestone for public health.”

Learn the facts about the ruling and how there is no true role for HTPs in public health.

Read More